These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

630 related articles for article (PubMed ID: 15838561)

  • 1. A controlled study of the effects of carvedilol on clinical events, left ventricular function and proinflammatory cytokines levels in patients with dilated cardiomyopathy.
    Tatli E; Kurum T
    Can J Cardiol; 2005 Mar; 21(4):344-8. PubMed ID: 15838561
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effects of carvedilol on right ventricular ejection fraction and cytokines levels in patients with systolic heart failure.
    Tatli E; Kurum T; Aktoz M; Buyuklu M
    Int J Cardiol; 2008 Apr; 125(2):273-6. PubMed ID: 18053592
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Effects of carvedilol on plasma levels of pro-inflammatory cytokines in patients with ischemic and nonischemic dilated cardiomyopathy.
    Kurum T; Tatli E; Yuksel M
    Tex Heart Inst J; 2007; 34(1):52-9. PubMed ID: 17420794
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Beneficial effects of pentoxifylline in patients with idiopathic dilated cardiomyopathy treated with angiotensin-converting enzyme inhibitors and carvedilol: results of a randomized study.
    Skudicky D; Bergemann A; Sliwa K; Candy G; Sareli P
    Circulation; 2001 Feb; 103(8):1083-8. PubMed ID: 11222470
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Carvedilol in children with cardiomyopathy: 3-year experience at a single institution.
    Rusconi P; Gómez-Marín O; Rossique-González M; Redha E; Marín JR; Lon-Young M; Wolff GS
    J Heart Lung Transplant; 2004 Jul; 23(7):832-8. PubMed ID: 15261177
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Effects of carvedilol on plasma levels of interleukin-6 and tumor necrosis factor-alpha in nine patients with dilated cardiomyopathy.
    Matsumura T; Tsushima K; Ohtaki E; Misu K; Tohbaru T; Asano R; Nagayama M; Kitahara K; Umemura J; Sumiyoshi T; Hosoda S
    J Cardiol; 2002 May; 39(5):253-7. PubMed ID: 12048901
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of initiating carvedilol before angiotensin-converting enzyme inhibitor therapy on cardiac function in newly diagnosed heart failure.
    Sliwa K; Norton GR; Kone N; Candy G; Kachope J; Woodiwiss AJ; Libhaber C; Sareli P; Essop R
    J Am Coll Cardiol; 2004 Nov; 44(9):1825-30. PubMed ID: 15519014
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Treatment of dilated cardiomyopathy with carvedilol in children.
    Erdoğan I; Ozer S; Karagöz T; Celiker A; Ozkutlu S; Alehan D
    Turk J Pediatr; 2009; 51(4):354-60. PubMed ID: 19950843
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Carvedilol improves left ventricular function and symptoms in chronic heart failure: a double-blind randomized study.
    Olsen SL; Gilbert EM; Renlund DG; Taylor DO; Yanowitz FD; Bristow MR
    J Am Coll Cardiol; 1995 May; 25(6):1225-31. PubMed ID: 7722114
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Arg389Gly-beta1-adrenergic receptors determine improvement in left ventricular systolic function in nonischemic cardiomyopathy patients with heart failure after chronic treatment with carvedilol.
    Chen L; Meyers D; Javorsky G; Burstow D; Lolekha P; Lucas M; Semmler AB; Savarimuthu SM; Fong KM; Yang IA; Atherton J; Galbraith AJ; Parsonage WA; Molenaar P
    Pharmacogenet Genomics; 2007 Nov; 17(11):941-9. PubMed ID: 18075464
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparative efficacy of nebivolol versus carvedilol on left ventricular function and exercise capacity in patients with nonischemic dilated cardiomyopathy. A 12-month study.
    Patrianakos AP; Parthenakis FI; Mavrakis HE; Diakakis GF; Chlouverakis GI; Vardas PE
    Am Heart J; 2005 Nov; 150(5):985. PubMed ID: 16290981
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Efficacy and safety of carvedilol in infants with dilated cardiomyopathy: a preliminary report.
    Gachara N; Prabhakaran S; Srinivas S; Farzana F; Krishnan U; Shah MJ
    Indian Heart J; 2001; 53(1):74-8. PubMed ID: 11456146
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Effects of carvedilol on systolic and diastolic left ventricular performance in idiopathic dilated cardiomyopathy or ischemic cardiomyopathy.
    Quaife RA; Gilbert EM; Christian PE; Datz FL; Mealey PC; Volkman K; Olsen SL; Bristow MR
    Am J Cardiol; 1996 Oct; 78(7):779-84. PubMed ID: 8857482
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Predicting response to carvedilol for the treatment of heart failure: a multivariate retrospective analysis.
    Schleman KA; Lindenfeld JA; Lowes BD; Bristow MR; Ferguson D; Wolfel EE; Abraham WT; Zisman LS
    J Card Fail; 2001 Mar; 7(1):4-12. PubMed ID: 11264544
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Effects of carvedilol on left ventricular function and oxidative stress in infants and children with idiopathic dilated cardiomyopathy: a 12-month, two-center, open-label study.
    Bajcetic M; Kokic Nikolic A; Djukic M; Kosutic J; Mitrovic J; Mijalkovic D; Jovanovic I; Simeunovic S; Spasic MB; Samardzic R
    Clin Ther; 2008 Apr; 30(4):702-14. PubMed ID: 18498919
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Carvedilol improves left atrial and left ventricular function and reserve in dilated cardiomyopathy after 1 year of treatment.
    Paraskevaidis I; Farmakis D; Parissis JT; Dodouras T; Filippatos G; Tsiapras D; Kremastinos DT
    J Card Fail; 2007 Mar; 13(2):108-13. PubMed ID: 17395050
    [TBL] [Abstract][Full Text] [Related]  

  • 17. A randomized trial of carvedilol after renin-angiotensin system inhibition in chronic Chagas cardiomyopathy.
    Botoni FA; Poole-Wilson PA; Ribeiro AL; Okonko DO; Oliveira BM; Pinto AS; Teixeira MM; Teixeira AL; Reis AM; Dantas JB; Ferreira CS; Tavares WC; Rocha MO
    Am Heart J; 2007 Apr; 153(4):544.e1-8. PubMed ID: 17383291
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Effects of carvedilol, a vasodilator-beta-blocker, in patients with congestive heart failure due to ischemic heart disease. Australia-New Zealand Heart Failure Research Collaborative Group.
    Circulation; 1995 Jul; 92(2):212-8. PubMed ID: 7600653
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dobutamine stress 99mTc-tetrofosmin quantitative gated SPECT predicts improvement of cardiac function after carvedilol treatment in patients with dilated cardiomyopathy.
    Kasama S; Toyama T; Kumakura H; Takayama Y; Ichikawa S; Tange S; Suzuki T; Kurabayashi M
    J Nucl Med; 2004 Nov; 45(11):1878-84. PubMed ID: 15534058
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Concentration of BNP, endothelin 1, pro-inflammatory cytokines (TNF-alpha, IL-6) and exercise capacity in patients with heart failure treated with carvedilol.
    Nessler J; Nessler B; Kitliński M; Gackowski A; Piwowarska W; Stepniewski M
    Kardiol Pol; 2008 Feb; 66(2):144-51; discussion 152-3. PubMed ID: 18344152
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 32.